Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. Research peptides discussed are not FDA-approved for human use. Always consult a licensed healthcare professional. See our full disclaimer.
Quick Answer: Pemvidutide is an investigational dual GLP-1 and glucagon receptor agonist from Altimmune, designed as a once-weekly injection for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Its mechanism overlaps closely with survodutide — both activate GLP-1 and glucagon pathways to combine appetite suppression with hepatic fat clearance and increased energy expenditure. In Phase 2 obesity trials pemvidutide produced ~15.6% placebo-adjusted weight loss at 48 weeks; in Phase 2 MASH trials it showed substantial liver fat reduction and MASH resolution. Pemvidutide is notable for positioning itself specifically at the intersection of obesity and liver disease rather than competing head-to-head on pure weight-loss numbers. Phase 3 trials are in planning as of 2026.
What Is Pemvidutide?
Pemvidutide (ALT-801) is a GLP-1 and glucagon receptor dual agonist developed by Altimmune. It is formulated as a once-weekly subcutaneous injection and positioned for obesity and MASH treatment. Pemvidutide joins survodutide, cotadutide, and retatrutide in the broader glucagon-containing next-generation metabolic peptide class.
Altimmune designed pemvidutide with a specific receptor activation ratio (balanced toward GLP-1 with meaningful glucagon component) intended to maximize liver fat clearance and weight loss while minimizing metabolic disruption.
Mechanism
Pemvidutide activates both receptors simultaneously. The GLP-1 component produces typical appetite suppression and insulin-sensitizing effects. The glucagon component drives hepatic fat mobilization and oxidation, increased resting metabolic rate, and satiety augmentation. The balance is calibrated so glucagon's glucose-elevating tendency is overridden by GLP-1's glucose-lowering action.
Beyond weight loss, pemvidutide's glucagon signaling directly addresses liver fat — a mechanism that pure GLP-1 agents address only indirectly through weight reduction.
Clinical Data
Obesity: MOMENTUM Phase 2
The MOMENTUM trial (Phase 2, 48 weeks) showed placebo-adjusted weight loss of approximately 15.6% at the highest pemvidutide dose (2.4 mg weekly). This places pemvidutide between semaglutide and tirzepatide in efficacy.
MASH: Phase 2
Pemvidutide demonstrated significant reductions in liver fat content (measured by MRI-PDFF) across dose ranges, with histological improvement in MASH activity at 24 weeks in early cohorts. Full Phase 2 MASH data have been reported with favorable results.
Phase 3
Phase 3 obesity and MASH trials are in planning or early enrollment as of 2026. Results are expected in 2027–2028.
Dosing and Administration
Based on Phase 2 data, the titration scheme is:
| Week | Dose (mg SC weekly) |
|---|---|
| 1–4 | 0.6 |
| 5–8 | 1.2 |
| 9–12 | 1.8 |
| 13+ | 2.4 (maintenance) |
As with all dual agonists, slow titration is essential to minimize GI side effects and allow glucagon-related metabolic adjustments.
Side Effects
Pemvidutide's side-effect profile is typical of GLP-1 agonists with some glucagon-related effects:
- Nausea, vomiting, diarrhea (most common)
- Mild blood pressure or heart rate changes from glucagon activation
- Modest effects on LDL cholesterol (glucagon-related)
- Gallbladder issues (typical GLP-1 class)
- Injection site reactions (minor)
The drug has been well-tolerated in Phase 2 trials with discontinuation rates comparable to semaglutide.
Pemvidutide vs Peers
| Drug | Mechanism | Weight Loss | MASH Focus |
|---|---|---|---|
| Pemvidutide | GLP-1 + glucagon | ~15.6% pa | Strong |
| Survodutide | GLP-1 + glucagon | ~19% pa | Strong |
| Retatrutide | GIP + GLP-1 + glucagon | ~24% pa | Strong (inferred) |
| Cotadutide | GLP-1 + glucagon | ~11% | Moderate |
| Tirzepatide | GIP + GLP-1 | ~22.5% | Moderate |
Pemvidutide's main positioning challenge is that survodutide has similar mechanism with somewhat greater reported weight loss. Pemvidutide's advantage may lie in tolerability or liver-specific outcomes.
Pemvidutide for MASH
MASH is a major unmet need. Pemvidutide's Phase 2 data show substantial improvements in liver fat and MASH histology, positioning it as a plausible future therapy in the MASH space alongside survodutide and resmetirom.
If approved for MASH, pemvidutide could become part of a dedicated MASH treatment toolkit rather than a pure obesity drug.
Regulatory and Access
Pemvidutide is still in clinical development with Phase 3 trials pending. FDA approval is expected no earlier than 2027–2028. Pricing and access at launch are uncertain but likely to follow GLP-1 class pricing (~$1,000+ monthly in US).
Bottom Line
Pemvidutide is one of several promising Phase 3-stage peptides with dual glucagon/GLP-1 action. Its main advantages are strong liver fat reduction and a well-tolerated profile; its main competitive challenge is survodutide's similar mechanism and somewhat stronger weight-loss data. For patients with obesity + MASH, pemvidutide may carve out a specific niche. For pure weight loss, tirzepatide and retatrutide remain more impressive. Final positioning depends on Phase 3 results over the next 18–24 months.
Recommended Research Vendors
For researchers sourcing compounds discussed in this article, the following vendors maintain third-party purity testing, transparent sourcing, and established reputations in the research peptide community. WolveStack earns a small commission on referred purchases, which funds our research and writing work — this does not affect our editorial evaluation of each vendor.
🧪 Ascension Research
Third-party tested research peptides. Transparent COAs, reliable sourcing, and fast shipping make Ascension a top choice for researchers.
Visit Ascension →🧬 Particle Peptides
Pharma-grade purity with full HPLC/MS certificates for every batch. Particle is known for clinical-grade quality and precision research protocols.
Visit Particle →💎 Limitless Life
Popular for novel and hard-to-source research compounds. Limitless offers a broad catalog of frontier peptides backed by third-party testing.
Visit Limitless →Frequently Asked Questions
No. Pemvidutide is in late-stage clinical development. Phase 3 trials for obesity and MASH are in planning or early enrollment. FDA approval is expected no earlier than 2027–2028.
Both are GLP-1/glucagon dual agonists, but with slightly different receptor activation profiles. Pemvidutide showed ~15.6% placebo-adjusted weight loss in Phase 2; survodutide showed ~19%. Pemvidutide's MASH data are strong; survodutide's are similarly impressive. Overall, survodutide appears slightly more potent for weight loss; both target MASH effectively.
Yes, that's a key indication. Pemvidutide's glucagon receptor activation drives hepatic fat clearance. Phase 2 data show substantial liver fat reductions and MASH improvements. Phase 3 MASH trials will determine formal approval.
Similar to other GLP-1 agonists: nausea, vomiting, diarrhea most common. Some glucagon-related effects including mild blood pressure changes and modest LDL elevation. Titration minimizes GI symptoms. Generally well-tolerated.
As with other GLP-1 class drugs, pemvidutide would likely combine safely with most medications. Specific drug-drug interaction studies are ongoing. Blood glucose monitoring is important for patients on insulin or sulfonylureas.
Altimmune is a clinical-stage biotechnology company focused on immunology and metabolic diseases. Pemvidutide is their lead asset in metabolic disease.
Pemvidutide produces more weight loss (~15.6% vs ~15% for semaglutide) and has specific liver benefits that semaglutide doesn't match. However, semaglutide has years of commercial use, broader insurance coverage, and a longer safety track record.
Phase 3 trials for pemvidutide are just beginning. Primary endpoint results are expected 2027–2028, with regulatory submission following approximately one year later. The FDA approval timeline could be 2028 at earliest.
You Might Also Like
About the Author
The WolveStack research team compiles peer-reviewed scientific literature, clinical trial data, and accumulated biohacking community experience to deliver evidence-first peptide education. Our guides reflect the current state of research and common practices in the researcher community, with emphasis on critical evaluation and transparent discussion of what is and isn't known.